View Item 

Show simple item record

2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease‐Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis

dc.contributor.authorSingh, Jasvinder A.en_US
dc.contributor.authorFurst, Daniel E.en_US
dc.contributor.authorBharat, Aseemen_US
dc.contributor.authorCurtis, Jeffrey R.en_US
dc.contributor.authorKavanaugh, Arthur F.en_US
dc.contributor.authorKremer, Joel M.en_US
dc.contributor.authorMoreland, Larry W.en_US
dc.contributor.authorO'Dell, Jamesen_US
dc.contributor.authorWinthrop, Kevin L.en_US
dc.contributor.authorBeukelman, Timothyen_US
dc.contributor.authorBridges, S. Louisen_US
dc.contributor.authorChatham, W. Winnen_US
dc.contributor.authorPaulus, Harold E.en_US
dc.contributor.authorSuarez‐almazor, Mariaen_US
dc.contributor.authorBombardier, Claireen_US
dc.contributor.authorDougados, Maximeen_US
dc.contributor.authorKhanna, Dineshen_US
dc.contributor.authorKing, Charles M.en_US
dc.contributor.authorLeong, Amye L.en_US
dc.contributor.authorMatteson, Eric L.en_US
dc.contributor.authorSchousboe, John T.en_US
dc.contributor.authorMoynihan, Eileenen_US
dc.contributor.authorKolba, Karen S.en_US
dc.contributor.authorJain, Archanaen_US
dc.contributor.authorVolkmann, Elizabeth R.en_US
dc.contributor.authorAgrawal, Harshen_US
dc.contributor.authorBae, Sangmeeen_US
dc.contributor.authorMudano, Amy S.en_US
dc.contributor.authorPatkar, Nivedita M.en_US
dc.contributor.authorSaag, Kenneth G.en_US
dc.date.accessioned2012-04-04T18:42:22Z
dc.date.available2013-06-11T19:15:41Zen_US
dc.date.issued2012-05en_US
dc.identifier.citationSingh, Jasvinder A.; Furst, Daniel E.; Bharat, Aseem; Curtis, Jeffrey R.; Kavanaugh, Arthur F.; Kremer, Joel M.; Moreland, Larry W.; O'Dell, James; Winthrop, Kevin L.; Beukelman, Timothy; Bridges, S. Louis; Chatham, W. Winn; Paulus, Harold E.; Suarez‐almazor, Maria ; Bombardier, Claire; Dougados, Maxime; Khanna, Dinesh; King, Charles M.; Leong, Amye L.; Matteson, Eric L.; Schousboe, John T.; Moynihan, Eileen; Kolba, Karen S.; Jain, Archana; Volkmann, Elizabeth R.; Agrawal, Harsh; Bae, Sangmee; Mudano, Amy S.; Patkar, Nivedita M.; Saag, Kenneth G. (2012). "2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Diseaseâ Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis ." Arthritis Care & Research 64(5): 625-639. <http://hdl.handle.net/2027.42/90529>en_US
dc.identifier.issn2151-464Xen_US
dc.identifier.issn2151-4658en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90529
dc.publisherJohn Wiley & Sons, Inc.en_US
dc.title2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease‐Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritisen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelGeriatricsen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan, Ann Arboren_US
dc.contributor.affiliationotherHighmark Medicare Services, Woodbury, New Jerseyen_US
dc.contributor.affiliationotherUniversity of Alabama at Birminghamen_US
dc.contributor.affiliationotherUniversity of California, Los Angelesen_US
dc.contributor.affiliationotherUniversity of California, San Diegoen_US
dc.contributor.affiliationotherAlbany Medical College, Albany, New Yorken_US
dc.contributor.affiliationotherUniversity of Pittsburgh, Pittsburgh, Pennsylvaniaen_US
dc.contributor.affiliationotherUniversity of Nebraska, Omahaen_US
dc.contributor.affiliationotherOregon Health and Science University, Portlanden_US
dc.contributor.affiliationotherUniversity of Texas MD Anderson Cancer Center, Houstonen_US
dc.contributor.affiliationotherToronto General Research Institute, Toronto, Ontario, Canadaen_US
dc.contributor.affiliationotherHôpital Cochin, Paris, Franceen_US
dc.contributor.affiliationotherNorth Mississippi Medical Center, Tupeloen_US
dc.contributor.affiliationotherHealthy Motivation, Santa Barbara, Californiaen_US
dc.contributor.affiliationotherMayo Clinic, Rochester, Minnesotaen_US
dc.contributor.affiliationotherUniversity of Minnesota and Park Nicollet Clinic, Minneapolisen_US
dc.contributor.affiliationotherPacific Arthritis Center, Santa Maria, Californiaen_US
dc.contributor.affiliationotherUniversity of Alabama at Birmingham, Faculty Office Tower 805B, 510 20th Street South, Birmingham, AL 35294en_US
dc.identifier.pmid22473917en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90529/1/21641_ftp.pdf
dc.identifier.doi10.1002/acr.21641en_US
dc.identifier.sourceArthritis Care & Researchen_US
dc.identifier.citedreferenceVencovsky J, Machacek S, Sedova L, Kafkova J, Gatterova J, Pesakova V, et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003; 62: 427 – 30.en_US
dc.identifier.citedreferenceMeyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003; 62: 120 – 6.en_US
dc.identifier.citedreferenceBerglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G, et al. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA‐RF at disease onset. Ann Rheum Dis 2006; 65: 453 – 8.en_US
dc.identifier.citedreferenceAtes A, Kinikli G, Turgay M, Akay G, Tokgoz G. Effects of rheumatoid factor isotypes on disease activity and severity in patients with rheumatoid arthritis: a comparative study. Clin Rheumatol 2007; 26: 538 – 45.en_US
dc.identifier.citedreferenceAgrawal S, Misra R, Aggarwal A. Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. Clin Rheumatol 2007; 26: 201 – 4.en_US
dc.identifier.citedreferenceWolfe F, Michaud K, Pincus T, Furst D, Keystone E. The Disease Activity Score is not suitable as the sole criterion for initiation and evaluation of anti–tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes. Arthritis Rheum 2005; 52: 3873 – 9.en_US
dc.identifier.citedreferenceWolfe F, Michaud K, Pincus T. A composite disease activity scale for clinical practice, observational studies, and clinical trials: the Patient Activity Scale (PAS/PAS‐II). J Rheumatol 2005; 32: 2410 – 5.en_US
dc.identifier.citedreferenceWells GA, Boers M, Shea B, Brooks PM, Simon LS, Strand CV, et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol 2005; 32: 2016 – 24.en_US
dc.identifier.citedreferencePincus T. The American College of Rheumatology (ACR) core data set and derivative “patient only” indices to assess rheumatoid arthritis. Clin Exp Rheumatol 2005; 23 Suppl: S109 – 13.en_US
dc.identifier.citedreferenceFDA, US Department of Health and Human Services. What is a serious adverse event? 2011. URL: http://www.fda.gov/safety/medwatch/howtoreport/ucm053087.htm.en_US
dc.identifier.citedreferenceSaag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762 – 84.en_US
dc.identifier.citedreferenceMcGory ML, Shekelle PG, Rubenstein LZ, Fink A, Ko CY. Developing quality indicators for elderly patients undergoing abdominal operations. J Am Coll Surg 2005; 201: 870 – 83.en_US
dc.identifier.citedreferenceShekelle P. The appropriateness method. Med Decis Making 2004; 24: 228 – 31.en_US
dc.identifier.citedreferenceShekelle PG, Park RE, Kahan JP, Leape LL, Kamberg CJ, Bernstein SJ. Sensitivity and specificity of the RAND/UCLA Appropriateness Method to identify the overuse and underuse of coronary revascularization and hysterectomy. J Clin Epidemiol 2001; 54: 1004 – 10.en_US
dc.identifier.citedreferenceSingh JA, Noorbaloochi S, Singh G. Golimumab for rheumatoid arthritis. Cochrane Database Syst Rev 2010; 1: CD008341.en_US
dc.identifier.citedreferenceSingh JA, Beg S, Lopez‐Olivo MA. Tocilizumab for rheumatoid arthritis. Cochrane Database Syst Rev 2010; 7: CD008331.en_US
dc.identifier.citedreferenceSingh JA, Christensen R, Wells GA, Suarez‐Almazor ME, Buchbinder R, Lopez‐Olivo MA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009; 4: CD007848.en_US
dc.identifier.citedreferenceRuiz Garcia V, Jobanputra P, Burls A, Cabello JB, Galvez Munoz JG, Saiz Cuenca ES, et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst Rev 2009; 2: CD007649.en_US
dc.identifier.citedreferenceLandis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159 – 74.en_US
dc.identifier.citedreferenceFelson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727 – 35.en_US
dc.identifier.citedreferenceAletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 2005; 52: 2625 – 36.en_US
dc.identifier.citedreferenceAletaha D, Smolen JS. The definition and measurement of disease modification in inflammatory rheumatic diseases. Rheum Dis Clin North Am 2006; 32: 9 – 44.en_US
dc.identifier.citedreferenceSmolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux‐Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease‐modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964 – 75.en_US
dc.identifier.citedreferenceArnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315 – 24.en_US
dc.identifier.citedreferenceAletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569 – 81.en_US
dc.identifier.citedreferenceBathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 22: 1586 – 93.en_US
dc.identifier.citedreferenceVan der Kooij SM, le Cessie S, Goekoop‐Ruiterman YP, de Vries‐Bouwstra JK, van Zeben D, Kerstens PJ, et al. Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1153 – 8.en_US
dc.identifier.citedreferenceSt.Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al, for the Active‐Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50: 3432 – 43.en_US
dc.identifier.citedreferenceSmolen JS, Han C, van der Heijde D, Emery P, Bathon JM, Keystone E, et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum 2006; 54: 716 – 22.en_US
dc.identifier.citedreferenceKimel M, Cifaldi M, Chen N, Revicki D. Adalimumab plus methotrexate improved SF‐36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. J Rheumatol 2008; 35: 206 – 15.en_US
dc.identifier.citedreferenceHan C, Smolen J, Kavanaugh A, St.Clair EW, Baker D, Bala M. Comparison of employability outcomes among patients with early or long‐standing rheumatoid arthritis. Arthritis Rheum 2008; 59: 510 – 4.en_US
dc.identifier.citedreferenceEmery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double‐blind, parallel treatment trial. Lancet 2008; 372: 375 – 82.en_US
dc.identifier.citedreferenceBejarano V, Quinn M, Conaghan PG, Reece R, Keenan AM, Walker D, et al, and the Yorkshire Early Arthritis Register Consortium. Effect of the early use of the anti–tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 2008; 59: 1467 – 74.en_US
dc.identifier.citedreferenceCDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Mortal Morb Wkly Rep 2000; 49: 1 – 51.en_US
dc.identifier.citedreferenceHurst JW, Morris DC, Alexander RW. The use of the New York Heart Association's classification of cardiovascular disease as part of the patient's complete Problem List. Clin Cardiol 1999; 22: 385 – 90.en_US
dc.identifier.citedreferenceChristensen E, Schlichting P, Fauerholdt L, Gluud C, Andersen PK, Juhl E, et al. Prognostic value of Child‐Turcotte criteria in medically treated cirrhosis. Hepatology 1984; 4: 430 – 5.en_US
dc.identifier.citedreferenceHunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112: e154 – 235.en_US
dc.identifier.citedreferenceFransen J, Stucki G, van Riel PL. Disease Activity Score (DAS), Disease Activity Score‐28 (DAS28), Rapid Assessment of Disease Activity in Rheumatology (RADAR), and Rheumatoid Arthritis Disease Activity Index (RADAI). Arthritis Rheum 2003; 49 Suppl: S214 – 24.en_US
dc.identifier.citedreferenceAletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005; 7: R796 – 806.en_US
dc.identifier.citedreferencePincus T, Yazici Y, Bergman M. A practical guide to scoring a Multi‐Dimensional Health Assessment Questionnaire (MDHAQ) and Routine Assessment of Patient Index Data (RAPID) scores in 10‐20 seconds for use in standard clinical care, without rulers, calculators, websites or computers. Best Pract Res Clin Rheumatol 2007; 21: 755 – 87.en_US
dc.identifier.citedreferenceFelson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011; 63: 573 – 86.en_US
dc.identifier.citedreferenceBresnihan B. Preventing joint damage as the best measure of biologic drug therapy. J Rheumatol Suppl 2002; 65: 39 – 43.en_US
dc.identifier.citedreferenceSmolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003; 42: 244 – 57.en_US
dc.identifier.citedreferenceWells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28‐joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C‐reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009; 68: 954 – 60.en_US
dc.identifier.citedreferenceBrook A, Corbett M. Radiographic changes in early rheumatoid disease. Ann Rheum Dis 1977; 36: 71 – 3.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
21641_ftp.pdf
Size:
153.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.